Could less hormone therapy be enough for High-Risk prostate cancer?

NCT ID NCT05100472

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a shorter course of hormone therapy (6 months instead of the usual longer duration) combined with targeted radiation can safely prevent high-risk prostate cancer from spreading. About 50 men with aggressive prostate cancer will receive hormone therapy, followed by brachytherapy and external beam radiation. The goal is to maintain cancer control while reducing side effects from hormones.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Androgen deprivation therapy (bicalutamide and leuprolide) plus brachytherapy and external beam radiation
What this could lead to: If successful, this could offer a way to treat high-risk prostate cancer with fewer hormone therapy side effects while still preventing the cancer from spreading.
What could go wrong: This is a small, early-phase trial (50 people) with no control group, so results may not apply broadly. The shorter hormone course might be less effective at preventing recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.